Company / Return on Equity (ROE)
NeoGenomics Laboratories, Inc. Return on Equity (ROE) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-12.9%
FY2025
5-year range
-14.4% / -0.8%
FY2021-FY2025
Trend
-48.1%
vs FY2024
Sector context
#113 of 148
Health Care
What the data says
NeoGenomics Laboratories, Inc. reports negative total equity of -12.9% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-12.9% in FY2025 with a 5-year CAGR of -13.5%.
Declined from -9.3% to -12.9% over the past 2 years.
Health Care sector context is included.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- +1.5pp
- 5-Year Change
- -13.5pp
- 10-Year Change
- -
Sector benchmark
Bottom 24% in Health CareTop 76% of 148This company -12.9% Sector average -3.2%
▼
-308.8% below sector average
Key checks
Key Insights
- In FY2025, return on equity (roe) decreased 48.1% year-over-year.
- Currently 9.8pp below the Health Care sector average.
- Peak return on equity (roe) was recorded in FY2019.
- Lowest return on equity (roe) in the period was in FY2022.
Company context
Key Data Points
- Altman Z-Score 0.56 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -12.9% | -48.1% |
| FY2024 | -8.7% | +6.6% |
| FY2023 | -9.3% | +35.4% |
| FY2022 | -14.4% | -1826.7% |
| FY2021 | -0.8% | -225.0% |
| FY2020 | 0.6% | -62.0% |
| FY2019 | 1.6% | +92.7% |
| FY2018 | 0.8% | +456.5% |
| FY2017 | -0.2% | +93.9% |
| FY2016 | -3.8% | -209.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026